Paper - WANFANG MED ONLINE

You Position: Home > Paper

肿瘤基因组图谱及其在卵巢上皮性癌相关研究中的应用进展

( views:181, downloads:140 )

Author:: No author available

Journal Title:: Chinese Journal of Obstetrics and Gynecology

Issue:: 2

DOI:: 10.3760/cma.j.issn.0529-567x.2015.02.016

Key Word:: No keyword available

Abstract：一、肿瘤基因组图谱计划的简介<br>　　1990年，人类基因组计划（human genome project，HGP）启动，该计划由多个国家参与，旨在对人类染色体30多亿个碱基对进行测定，明确基因及其在染色体上的位置，绘制基因组图谱，并达到破解人类遗传信息的最终目的。至2005年，人类基因组的测序工作已经完成。

Reference

[1]邓祯祥,王文辉,李金明.整合卵巢癌染色体拷贝数变异与差异表达基因的生物信息学分析[J].2014,(6).
[2].Prognostically relevant gene signatures of high-grade serous ovarian carcinoma[J].2013,123(1).
[3]David W,Kindelberger.Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.[J].2007,31.
[4]Aaron D. Goldberg,C. David Allis,Emily Bernstein.Epigenetics: A Landscape Takes Shape[J].2007,128(4).
[5]Chad J, Creighton,Anadulce, Hernandez-Herrera,Anders, Jacobsen,etc.Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma.[J].2012,7(3).
[6]Jaenisch R,Bird A.Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals.[J].2003,33(Suppl.).
[7].The Hallmarks of Cancer[J].2000,100(1).
[8]Chan,J.K.,Kiet,T.K.,Blansit,K.,etc.MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer[J].2014,133(3).
[9]Fiegler H,Shapero MH,Carson AR,etc.Global variation in copy number in the human genome[J].2006,444(7118).
[10]Sohn,I.,Sung,C.O.,Jung,W.Y..Somatic hypermutation and outcomes of platinum based chemotherapy in patients with high grade serous ovarian cancer[J].2012,126(1).
[11]Muller PA,Vousden KH,Norman JC.P53 and Its Mutants in Tumor Cell Migration and Invasion.[J].2011,192(2).
[12]Li, Chen,Jianhua, Xuan,Jinghua, Gu,etc.Integrative network analysis to identify aberrant pathway networks in ovarian cancer.[J].2012.
[13]Kang, Hyo Jeong,Chun, Sung-Min,Kim, Kyu-Rae.Clinical Relevance of Gain-Of-Function Mutations of p53 in High-Grade Serous Ovarian Carcinoma.[J].2013,8(8).
[14]Cen, Zhang,Juan, Liu,Yingjian, Liang,etc.Tumour-associated mutant p53 drives the Warburg effect.[J].2013,4.
[15]Vousden,K.H.,Muller,P.A.J..P53 mutations in cancer[J].2013,15(1).
[16]Richard W, Tothill,Anna V, Tinker,Joshy, George,etc.Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.[J].2008,14.
[17]Shih IeM,Nakayama K,Wu G,etc.Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma.[J].2011,24(5).
[18]Valerie McGuire,Christine A. Jesser,Alice S. Whittemore.Survival among U.S. Women with Invasive Epithelial Ovarian Cancer[J].2002,84(3).
[19]Sadetzki S,Ben-David Y,Friedman E,etc.Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.[J].2008,26(1).
[20]Levine DA,Chi DS,Dao F,etc.An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).[J].2012,124(1).
[21]Dao,F.,Barakat,R.R.,Chi,D.S.,etc.Validated gene targets associated with curatively treated advanced serous ovarian carcinoma[J].2013,128(3).
[22]Sheng-fa Wang,Shi-dong Xu,Hai Xu,etc.MicroRNA-378 is associated with non-small cell lung cancer brain metastasis by promoting cell migration, invasion and tumor angiogenesis.[J].2012,29(3).
[23]Miron A,Medeiros F,Gordon RW,etc.A candidate precursor to serous carcinoma that originates in the distal fallopian tube.[J].2007,211(1).
[24]Michael L Friedlander,Martin Richard Stockler,Phyllis Butow,etc.Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: time to think differently?[J].2013,31(18).
[25]Crum CP,Kindelberger DW,Callahan MJ,etc.Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.[J].2007,25(25).
[26]Fabiola, Medeiros,Michael G, Muto,Yonghee, Lee,etc.The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.[J].2006,30(2).
[27]Fountain MD,Yu,Creighton CJ.Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.[J].2010,70(5).
[28]Birkbak, Nicolai Juul,Kochupurakkal, Bose,Izarzugaza, Jose M. G.,etc.Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations.[J].2013,8(11).
[29]Gregory D, Miles,Michael, Seiler,Lorna, Rodriguez,etc.Identifying microRNA/mRNA dysregulations in ovarian cancer.[J].2012,5.
[30].Integrated genomic analyses of ovarian carcinoma[J].2011,474(Jun.30 TN.7353).
[31]Wan, Ying-Wooi,Mach, Claire M.,Allen, Genevera I.,etc.On the Reproducibility of TCGA Ovarian Cancer MicroRNA Profiles.[J].2014,9(1).
[32]Mok,S.C.,Deavers,M.T.,Wong,K.-K.,etc.Poor survival with wild-type TP53 ovarian cancer?[J].2013,130(3).
[33]Dai,W.,Zeller,C.,Masrour,N.,etc.Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer[J].2013,19(20).
[34]Cope,L.,Wang,T.-L.,Wu,R.-C.,etc.High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome[J].2013,128(3).
[35]Yong Han,Hao Huang,Zhen Xiao,etc.Integrated Analysis of Gene Expression Profiles Associated with Response of Platinum/Paclitaxel-Based Treatment in Epithelial Ovarian Cancer.[J].2012,7(12).
[36]Barnholtz-Sloan, J. S.,Schwartz, A. G.,Qureshi, F.,etc.Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades[J].2003,189(4).